|
(MoneyNewsWire.Net, April 29, 2016 )
Baricitinib (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
To Browse a Full Report with TOC: http://www.researchmoz.us/baricitinib-rheumatoid-arthritis-forecast-and-market-analysis-to-2023-report.html
Eli Lilly and Incyte are jointly developing baricitinib, an oral JAK inhibitor, for the treatment of patients with moderate to severe RA. Baricitinib has roughly equal affinity for JAK1 and JAK2, preventing the intracellular signaling cascades that lead to the production of IL-6 and IL-23, thereby reducing inflammation.
Scope
- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Baricitinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Baricitinib for the top 10 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.
1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 16
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 30
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 31
Figure 5: Flowchart for the Management of RA - EULAR 2013 32
Figure 6: RA - Phase II-III Pipeline, 2014 55
Figure 7: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023 59
Figure 8: Clinical and Commercial Positioning of Baricitinib 68
To Download Sample Report With TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=247176
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Baricitinib performance.
- Obtain sales forecast for Baricitinib from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare, +1–518–621–2074
USA-Canada Toll Free: 866–997–4948
Email: sales@researchmoz.us
WebSite:http://www.researchmoz.us/
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
|
